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Abstract	
	
	
Retinitis	pigmentosa	(RP)	is	a	group	of	inherited	dystrophic	retinal	disease	that	affects	1	of	
4000	people	worldwide.	It	gradually	leads	to	visual	loss	through	retinal	neurodegeneration	
with	a	slow	and	progressive	process.	The	underlying	mechanisms	of	the	cell	death	are	now	
well	studied	but	their	interactions	remain	uncertain.	Just	before	the	death	of	the	
photoreceptor,	some	of	the	cell	cycle	proteins	are	reactivated	and	may	play	an	important	
role.	In	the	laboratory,	some	microRNAs	have	been	identified	during	the	photoreceptor	
relapse	of	the	Rd1	mouse	model	of	retinal	degeneration.	The	objectives	of	this	study	is	to	
understand	the	potential	role	of	the	miR-31	in	the	control	of	specific	cell	cycle	proteins.	For	
this	experiment,	a	mouse	photoreceptor-like	cell	line	(661W)	has	been	cultured	and	
transfected	with	a	plasmid	coding	for	miR-31	and	GFP	or	a	scramble	sequence	and	GFP	
(control).	Western	Blot	and	qPCR	allowed	us	to	evaluate	respectively	the	cell	cycle	protein	
status	and	the	corresponding	mRNA	status	in	relation	to	the	miR-31	overexpression.	
Our	experiment	revealed	that	miR-31	downregulates	E2f1	cell	cycle	protein	in	661W	cells.	
These	results	must	be	confirmed	with	supplementary	experiments	in	vivo	studies	in	Rd1	
mouse	retina.		
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Introduction			
	
1. The	retina		
	
The	retina	is	the	nervous	layer	of	the	eye.	Its	role	is	to	detect	the	visual	world	and	send	it	to	
the	brain	in	order	to	create	the	visual	perception.	
The	retina	is	arranged	in	different	layers	of	cells.	The	most	important	one	–	the	outer	nuclear	
layer-	 is	 composed	 from	 the	 photoreceptors:	 the	 rods	 and	 the	 cones,	 which	 are	 light-
sensitive	 cells	 and	 convert	 the	 photons	 energy	 into	 an	 electrical	 signal	 and	 send	 it	 via	
interneurons	and	the	optic	nerve	to	the	brain	for	visual	processing.	The	adult	human	retina	
contains	more	than	5	million	cones	and	about	120	million	rods	(1).	Rod	function	is	to	detect	
dim	light	in	an	achromatic	vision,	while	cones	are	important	for	the	fine	visual	acuity	and	for	
perceiving	colours	during	the	day.	
Thus	said,	if	the	retina	is	damaged,	permanent	vision	loss	or	blindness	can	occur.	Age-related	
macular	 degeneration,	 diabetic	 retinopathy	 or	 retinitis	 pigmentosa	 (RP)	 are	 the	 most	
common	retinal	diseases.	The	RP	is	going	to	be	our	subject	of	interest.	
	
2. Retinitis	pigmentosa	
	
Introduction,	epidemiology	and	inheritance	patterns	
	
Retinitis	 pigmentosa	 is	 composed	 of	 inherited	 dystrophic	 retinal	 diseases,	 which	 are	
characterized	by	progressive	degeneration	 and	dysfunction	of	 the	 retina.	 The	 terminology	
“retinitis”	is	not	accurate,	since	it	is	not	an	inflammatory	disease.	Other	terms	like	“rod-cone	
dystrophy”,	“inherited	retinal	dystrophy”	or	“pigmentary	retinopathy”	may	be	used.	
It	 affects	1	of	4000	 individuals	 (2)	 so	more	 than	1,5	million	 individuals	worldwide.	 It	 is	 an	
early	onset	disease	which	usually	begins	between	5	and	30	years	old.		
It	may	be	inherited	as	a	dominant,	recessive,	or	X-linked	trait	or	can	occur	as	a	sporadically	
mutation	(3).	Most	of	the	time	this	disorder	 is	 isolated	but	also	can	be	part	of	a	syndrome	
(about	20	–	30%	of	 the	 cases).	 There	are	more	 than	30	RP-associated	 syndromes	 (4).	 The	
Usher’s	 syndrome	 (associated	 with	 hearing	 loss	 and	 ataxia)	 (5)	 and	 the	 Bardet-Biedl	
syndrome	(associated	with	obesity,	cognitive	impairment,	polydactyly	and	renal	disease)	are	
the	 two	 most	 frequent.	 More	 than	 100	 mutated	 genes	 have	 been	 related	 to	 retinitis	
pigmentosa	(https://www.omim.org),	but	their	underlying	mechanisms	remain	for	the	most	
unknown.	
	
Clinical	manifestations	
	
RP	has	very	heterogeneous	manifestations	of	symptoms,	it	first	can	occur	during	childhood,	
whereas	 some	 other	 patients	 will	 remain	 asymptomatic	 until	 mid-adulthood.	 One	 of	 the	
earliest	symptoms	is	night	blindness,	also	known	as	nyctalopia.	Due	to	constant	presence	of	
artificial	 light	during	night	time,	this	symptom	may	be	never	noticed	by	some	patients	and	
the	identification	of	the	disease	can	be	delayed.	Another	common	feature	is	the	progressive	
constriction	 of	 the	 visual	 fields.	 First,	 the	 patient	 will	 notice	 a	 loss	 of	 the	mid-peripheral	
visual	 field,	 which	will	 evolve	 to	 the	 loss	 of	 far-peripheral	 vision.	 Then,	 they	will	 develop	
tunnel	vision	and	eventually	lose	their	central	vision	about	age	30	or	much	earlier	depending	
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on	 the	mutation.	 A	 typical,	 but	 late-onset	manifestation	 of	 the	 RP,	 is	 a	 decreasing	 visual	
acuity,	due	to	loss	of	the	cones,	leading	finally	to	blindness.	
	
Diagnostics,	treatments	and	prognosis	
	
The	 diagnostic	 of	 retinitis	 pigmentosa	 can	 be	 done	with	 the	 combination	 of	 the	 patient’s	
history	 and	 some	 complementary	 examination.	 One	 of	 the	most	 important	 assessment	 is	
done	with	the	fundus	exam,	on	which	we	can	see	pigmentary	changes,	as	dark	spots	in	the	
periphery	 of	 the	 retina,	 and	 pallor	 on	 the	 optic	 nerve.	 A	 patient	 with	 RP	 will	 have	 a	
constrictive	 visual-fields	 measured	 by	 the	 Goldman	 perimetry	 and	 the	 ERG	 (electro-
retinogram;	which	measures	the	electrical	response	of	the	retina	to	light	stimuli)	will	show	
reduced	response	amplitudes	and	a	delay	in	their	timing	(6).		
No	 approved	 treatment	 currently	 exists	 (7)	 and	 this	 disease	 often	 leads	 to	 blindness.	
Actually,	 research	 is	 focused	 on	 the	 slow-down	 of	 the	 evolution	 of	 the	 disease	 with	
strategies	like	gene	therapy,	cell	transplantation	and	some	treatment	like	retinal	prosthesis	
are	actually	tested	(8).	
	
3. Retinal	neurodegeneration			
	
The	mechanisms	at	the	origin	of	the	photoreceptor’s	death	in	the	RP	are	now	well	studied.	
Initially,	 it	 was	 thought	 that	 retinal	 photoreceptor’s	 death	 was	 due	 to	 mechanism	 like	
apoptosis	 (9).	 However,	 neurodegeneration	 in	 photoreceptor	 seems	 to	 be	 a	much	 slower	
mechanism	 than	 apoptosis	 and	 does	 not	 involve	 the	main	 actors	 inducing	 apoptosis	 (10).	
Distinct	pathways	are	implied.	In	fact,	studies	show	that	the	underlying	mechanism	of	retinal	
degeneration	is	more	complex.	
Retina	 from	 a	 mouse	 model	 with	 deficient	 gene	 for	 the	 ß	 subunit	 of	 phosphodiesterase	
(PDE6ß),	Rd1	mice,	 are	 habitually	 used	 for	 the	 investigation	 on	 retinal	 degeneration	 (11).	
Many	cellular	pathways	were	observed	to	be	activated	or	altered	during	the	photoreceptor	
degeneration	 process.	 For	 instance,	 it	 was	 seen	 that	 cGMP	 (Cyclic	 guanosine	
monophosphate)	and	PKG	(Protein	kinase	G);	which	are	two	well-known	regulators	of	intra-
cellular	activity,	had	an	 increased	 level	 in	 these	Rd1	mice,	and	that	 their	 inhibition	 in	vitro	
could	 lead	 to	 moderate	 cell	 rescue	 (12).	 Other	 processes	 like	 calpain-type	 protease	
activation	 (13),	 increased	 calcium	 (14)	 and	 oxidative	 stress	 (15)	 are	 also	 fairly	 suspected.	
Moreover,	an	increased	PARP	(-protein	involved	in	the	DNA	repair)	level	was	also	identified	
in	 Rd1	 mice	 (16)	 and	 was	 therefore	 a	 well-studied	 protein	 for	 the	 retinal	 degeneration.	
Therefore,	 an	 alternative	molecular	 pathway	 to	 cell	 death	 degeneration	 involving	 CREB	 (-
transcription	 factor)	 downregulation,	 oxidative	 stress,	 PARP	 overactivation	 and	 cyclic	
nucleotide	deregulation	was	proposed	(17),	but	the	attempts	to	protect	the	photoreceptors	
cells	from	death	 in	Rd1	 retina	by	acting	on	these	pathways	are	not	fully	satisfying.	A	more	
recent	study,	which	alternatively	investigated	the	cell	cycle	proteins	in	Rd1	retina,	found	that	
these	proteins	were	increased	in	photoreceptor	before	death	(18)	and	that	a	reduced	level	
of	 BMI1	 (polycomb	 group	 protein	 regulating	 proliferation)	 could	 lead	 to	 a	 significant	 	 cell	
rescue.		Indeed,	some	cell	cycle	protein	may	have	a	second	role	in	certain	post-mitotic	cells	
(19).	 The	 cell	 cycle	 is	 therefore	 reactivated	 before	 the	 death	 of	 the	 photoreceptors	 (20).	
Analogous	results	were	found	for	neurological	degenerative	diseases	as	Alzheimer	(21)	and	
Parkinson	disease	(22)	which	comforts	us	in	the	idea	that	retinal	degeneration	is	very	similar	
to	neurodegeneration	in	the	whole	nervous	system.	The	inhibition	of	the	re-entry	in	the	cell	
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cycle	 in	 Rd1	 retina	 appears	 to	 cause	 a	 massive	 cell	 protection	 (17,	 22)	 and	 this	 could	
consequently	lead	to	potential	new	pharmacological	treatment.	This	all	brought	us	to	focus	
our	study	on	the	cell	cycle	protein,	as	we	suspect	them	to	have	a	major	role	 in	the	retinal	
neurodegeneration.	
	
4. MicroRNA-31	
	
MicroRNA	(miR)	are	small	non-coding	RNA,	ranging	from	21	to	25	nucleotides	in	lenght.	They	
are	 a	major	 class	 of	 regulatory	molecule	 in	 animals	 and	 plants	 (24).	 They	 can	 control	 the	
genetic	 expression	 at	 a	 post-transcriptional	 level	 by	 binding	 the	 3’-untranslated	 region	
(3’UTR)	of	the	messenger	RNA	(mRNA),	and	induce	an	inhibition	of	the	expression.		
MiRs	are	more	and	more	studied	as	we	slowly	discover	considerable	 role	 in	development,	
homeostasis,	differentiation	and	especially	proliferation.	Depending	on	the	context,	miR	can	
promote	 cancer	 cell	 proliferation	 (25)	 as	 an	 oncogene;	 or	 on	 the	 contrary,	 be	 a	 tumor	
suppressor	as	in	the	gastric	cancer		(26)	or	in	the	ovarian	carcinoma	(27).	Their	association	
with	the	cell	cycle	is	admitted	(28)	and	we	know	them	to	be	involved	in	retinal	diseases	since	
they	have	been	identified	as	modulating	diabetic	retinopathy	(29).	
The	role	of	the	miR-31	has	been	studied	and	results	showed	that	it	promotes	angiogenesis	
(30),	cancer	cell	proliferation	in	colorectal	carcinoma	(31)	and	is	reduced	in	ischemic	retinas	
(32).	 MiR-31	 also	 have	 opposite	 functions	 depending	 on	 the	 tumoral	 context	 (33).	
Furthermore,	a	cell	cycle	protein,	E2f2,	has	been	identified	as	being	a	target	of	miR-31	(34),	
which	brought	us	to	assume	that,	among	other	miRs,	miR-31	was	a	main	regulator	of	cell-
cycle	protein.	By	comparing	Rd1	retina	with	wt	(wild	type)	retina,	our	lab	recently	evidenced	
a	considerable	decreased	amount	of	miR-31	in	the	retinal	degeneration	and	therefore,	this	
reduced	 quantity	 is	 suspected	 to	 be	 associated	 with	 the	 cell	 cycle	 protein	 activity.	 Our	
hypothesis	was	that	an	increased	miR-31	concentration	in	Rd1	retina	will	block	the	cell	cycle	
re-entry	and	thus	slow	down	the	cell	death	process.		
	
Aims	of	the	study	
	
The	objective	of	our	experiment	is	to	understand	the	effect	of	a	miR-31	overexpression	on	
retinal	cell	proliferation	and	cell	cycle	protein.	For	that,	we	decided	to	transfect	a	plasmid	
expressing	miR-31	in	661W	photoreceptor-like	cells	and	evaluate	through	Western-Blot	and	
RT-qPCR	the	effect	it	can	have	on	proteins	and	genes	regulating	the	cell	cycle	such	as	E2F1,	
CDK4,	E2f4,	FoxM1	and	Chk1.	Based	on	what	was	previously	introduced,	we	expected	a	
decreased	amount	of	these	targets.	
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Materials	and	methods		
	
	
1. Plasmid	and	cell	line	
	
A	miR-31	plasmid,	which	was	composed	of	pEZX-MR04	vector	with	an	antibiotic	resistant	
gene,	a	GFP-expressing	gene	and	a	CMV	promoter,	was	used	during	the	experiment.	As	well	
as	a	GFP-expressing	plasmid.		
The	cell	line	tested	on	this	study	was	the	661W	cell	line.	
	
2. Plasmid	amplification		
	
One	 of	 the	 first	 steps	 was	 to	 amplify	 our	 DNA	 plasmids	 expressing	 the	 miR-31	 coding	
sequence	and	GFP	control	into	a	lot	bigger	amount	in	the	process	called	transformation.	
For	bacterial	transformation,	we	used	the	DH5	alpha	electro	competent	cells.	1	µL	of	each	
plasmid	was	 incubated	with	 50	 µL	 aliquot	 of	 DH5	 alpha,	well	mixed	with	 gentle	 agitation	
before	electroporation	 (with	BioRad	Micropulser™).	After	1	h	 incubation	of	 the	mixture	 in	
minimal	medium	 (S.O.C),	20	µL	of	 the	cell	 solution	were	plated	on	LB	agar	with	ampicillin	
antibiotics	 for	 selection	 of	 successful	 transformants.	 For	 homogeneous	 distribution	 of	 the	
cell	suspension	on	the	LB	agar	plate,	we	added	autoclaved	glass	beads	(4	mm	diameter)	and	
did	 a	 gently	 shake	 to	 spread	 the	 cells.	 The	plate	was	 then	 incubated	at	 37°C	overnight	 to	
allowed	colonies	to	form.	
	
3. Bacterial	growth	and	prepping		
	
The	next	day,	we	used	a	pipette	 tips	 to	carefully	pinch	a	 single	colony	and	 transfer	 it	 into	
tube	 containing	 a	 mix	 of	 2	 mL	 of	 LB	 medium	 and	 2	 µL	 of	 ampicillin.	 The	 mix	 was	 then	
incubated	at	37°C	incubator,	300	rpm	for	more	than	6	hours.	1	mL	of	the	mini	culture	was	
used	 for	 large	 scale	 DNA	 amplification	 in	 500	 mL	 Erlenmeyer	 containing	 200	 mL	 of	 LB	
medium	and	200	µL	of	ampicillin	overnight	at	37°C,	300	rpm.	
	
4. DNA	purification		
	
This	bacterial	proliferation	possesses	a	great	number	of	DNA	which	express	the	miR-31	gene.	
The	next	objective	was	to	isolate	and	collect	the	DNA.	To	this	end,	we	used	a	commercial	kit,	
NucleoBond®	 maxi,	 and	 carefully	 followed	 the	 manufacturer’s	 instructions.	 After	 the	 cell	
lysis	with	several	buffers,	DNA	was	bind	to	the	column	filters	and	was	collected	in	a	new	ent	
through	the	gravity.	DNA	precipitation	was	performed	with	room	temperature	isopropanol,	
followed	by	a	centrifugation	at	15'000	g	for	45	minutes	at	4°C.	Then,	ethanol	70%	allowed	
the	 solution	 to	 be	 correctly	 washed,	 before	 being	 extracted	 after	 the	 centrifugation	 at	
15'000	g	for	5	minutes	at	4°C.	Purified	DNA	was	reconstituted	in	50	µL	of	sterile	HBSS	and	1	
µL	was	assayed	on	-NanoDrop®-	to	assess	the	DNA	concentration	and	purity.		
	 	
	 -	8	-	
5. 661W	cell	culture	and	growth	assay	
	
The	 661W	 cells	were	 cultured	 in	Dulbecco’s	modified	 Eagle’s	medium	 (DMEM),	 10%	 fetal	
bovine	serum	(FBS),	1%	penicillin/streptomycin	(P/S)	antibiotic	and	0,5	mM	of	ß-mercapto-
ethanol,	in	humidified	incubator	at	37°C,	and	5%	CO2.	The	cells	were	maintained	in		
culture	flasks,	usually	150	mm2	or	75	mm2	until	80%	to	90%	of	confluence,	and	media	were	
refreshed	 every	 4	 days.	Our	 passaging	 process	was	 as	 follow:	 the	medium	was	 aspirated;	
adherent	cells	were	washed	with	5	mL	of	Hank's	balanced	salt	solution	(HBSS)	during	a	few	
seconds,	then	detached	with	0,5	mL	of	Trypsin,	during	3	minutes	at	37°C	and	peeling	of	was	
inhibited	with	complete	media.	Cells	were	pelleted	by	centrifugation	 for	3	minutes	at	800	
turn	 per	 minute	 and	 then	 re-suspended	 in	 5	 mL	 of	 DMEM	 medium.	 We	 then	 took	 the	
necessary	proportion	of	volume,	according	to	the	desired	passaging,	to	seed	in	a	new	flask.	
Finally,	we	 checked	 the	 flasks	 at	 the	microscope	 to	 ensure	 that	 the	 suspended	 cells	were	
well	separated	and	free	of	aggregates,	before	incubating	the	flasks	at	37°C.	
	
6. Transfection	of	661W	cells	with	vector	expressing	micro-RNA		
	
Transient	 transfection	 is	 the	 introduction	of	 purified	DNA	 into	 a	 cell.	 It	 can	 be	 performed	
through	different	techniques	such	as	electroporation,	calcium	phosphate	or	lipofection.	We	
used	this	last	technique	for	our	transfection:	a	cationic	lipid	was	mixed	with	the	DNA	to	form	
liposome,	 this	 complex	will	 then	 fuse	with	 the	membrane	of	 the	 target	 cell,	 and	drop	 the	
DNA	material	inside.	
About	12	to	24	hours	before	the	transfection,	1.2x	105	and	6x104	cells	were	seeded	on	12-
well	 plates	 (in	 2	 mL	 of	 growth	 medium)	 or	 24-well	 plates	 (1	 mL	 of	 growth	 medium)	
respectively,	so	that	the	confluence	will	be	about	70-80%	during	the	transfection.		
The	 transfection	 was	 performed	 in	 triplicate	 for	 each	 plasmid,	 using	 the	 HBSS	 buffer	 as	
control.	 Cells	 were	 transfected	 with	 lipofectamine®	 2000	 transfection	 reagents	 and	
lipofectamine®	3000	transfection	reagents	according	to	the	manufacturer	protocol.	Briefly,	
the	actual	cell	medium	in	the	well	plate	was	aspirated	and	replaced	with	OPTI-MEM	which	is	
a	 reduced	 serum	 media.	 The	 following	 process	 is	 described	 for	 one	 12-well,	 and	 was	
repeated	for	the	necessary	number	of	wells.	In	a	first	tube,	lipofectamine	reagent	2	µL	was	
diluted	in	OPTI-MEM	50	µL	and	well	mixed	by	2-3	seconds	of	vortex.	In	another	tube,	1	µg	of	
DNA	was	diluted	in	50	µL	of	OPTI-MEM,	and	2	µL	of	P3000	reagents	was	added.	The	diluted	
DNA	 (and	P3000	 reagents)	was	 added	drop	by	drop	 in	 the	 lipofectamine	 tube,	which	was	
incubated	during	5	–	10	minutes	at	room	temperature.	After	the	DNA-lipid	complex	was	well	
formed,	 100	 µL	 of	 this	 mix	 was	 gently	 distributed	 in	 the	 corresponding	 well	 and	 then	
incubated	at	37°C	so	that	the	DNA	complex	could	be	fully	 integrated	and	expressed	 in	the	
661W	 cells.	 The	media	was	 replaced	 6	 h	 post-transfection	 and	 the	 plates	were	 incubated	
back	in	the	incubator	for	48	h	to	allow	transgene	expression.	
	
7. Generation	of	total	cell	homogenate	
	
The	 cells	 were	 harvested	 by	 scraping,	 and	 transferred	 into	 a	 1.5	 mL	 micro	 centrifuge	
Eppendorf	 tube.	 Then	 pelleted	 at	 300	 g,	 4°C	 during	 10	 minutes.	 Cells	 were	 washed	 in	
phosphate	 buffer	 saline	 (PBS)	 500	 µL,	 pelleted	 as	 above,	 and	 lysed	 in	 150	 µL	 of	
Radioimmunoprecipitation	 assay	 (RIPA)	 Lysis	 Buffer	 (10	mM	Tris	 [pH	 8],	 1	mM	EDTA,	 140	
mM	 NaCl,	 1%	 Triton,	 0,1%	 SDS,	 0,1%	 Na-deoxycholate)	 with	 cell	 lysis	 supplements	 (1%	
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proteases	 inhibitors	 cocktails,	 1%	 phosphatases	 inhibitors,	 1	 mM	 phenylmethylsulfonyl	
fluoride	(pmsf)).	The	cells	were	lysed	up	and	down	with	pipette	and	then	incubated	on	ice	
for	 30	 minutes	 with	 constant	 vortexing	 each	 5	 to	 7	 minutes.	 The	 cell	 debris	 was	 then	
pelleted	 by	 centrifugation	 16’000	 g,	 at	 4°C	 during	 10	 minutes.	 The	 supernatant,	 which	
contains	 the	 whole	 cell	 lysate,	 were	 finally	 collected	 into	 a	 clean	 Eppendorf	 tube	 and	
immediately	stored	at	-80°C	until	the	day	of	analysis.	
	
8. BCA	assay	
	
Bicinchoninic	 acid	 assay	 (BCA	 assay)	 is	 a	 colorimetric	 technique	 that	 measure	 the	 total	
concentration	 of	 protein	 in	 a	 solution.	 Our	 BCA	 assay	 was	 done	 in	 a	 96-well	 transparent	
plate.	First,	we	prepared	the	standard	solution,	with	a	serial	dilution	from	the	stock	solution	
at	 2	 µg/µL	 bovine	 serum	 albumin	 (BSA)	 diluted	 in	 our	 RIPA	 lysis	 buffer,	 so	 that	 the	 BSA	
concentration	 was	 known,	 in	 a	 final	 volume	 of	 50	 µL.	 Next,	 the	 sample	 dilution	 was	
performed,	with	5	µL	of	sample	diluted	in	45	µL	of	RIPA	lysis	buffer.	All	the	solutions	were	
then	well	mixed	up	and	divided	in	two,	by	pipetting	25	µL	of	each	well	side	down	to	a	clear	
well,	 for	 a	 final	 volume	 of	 25	 µL.	 BCA	 reagents	 mix	 of	 200	 µL	 were	 added	 in	 each	 well,	
followed	by	a	gently	 shaking	during	30	seconds	at	 room	temperature,	and	 then	 incubated	
during	 30	 minutes	 at	 37°C.	 Finally,	 the	 absorbance	 was	 read	 on	 MRX	 II	 microplate	
absorbance	reader	(Dynex	Technologies)	at	a	wavelength	of	562	nm.	
	
9. Western	blot	analysis		
	
Western	 blot	 is	 a	 biomoecular	 technique	 that	 allows	 the	 detection	 and	 identification	 of	
proteins	in	a	certain	solution.	It	uses	antibodies:	the	primary	antibody,	which	is	specific	for	a	
protein	of	 interest,	and	the	secondary	antibody,	which	binds	the	first	one	and	permits	the	
detection	 and	 visualization	 through	 chemiluminescence,	 fluorescence	 or	 other	 detection	
techniques.	
Based	on	the	BCA	assays,	the	total	protein	of	the	samples	sets	was	normalized	to	the	same	
concentration.	The	samples	were	mixed	with	protein	loading	buffer	(5x)	and	boiled	at	95°C	
during	5	min	for	denaturation.		
15	µL	of	protein	sample	(and	2,5	µL	of	protein	marker)	were	resolved	on	10%	Polyacrylamide	
gel	electrophoresis	(Acryl	5	mL,	1,5M	Tris	[pH	8.8]	5	mL,	20%	SDS,	H2O	9,8	mL,	10%	APS	200	
µL,	Temed	8	µL)	at	constant	140	V	for	70	minutes.	This	process	allows	the	protein	with	an	
electrical	charge	to	migrate	through	the	gel,	according	to	their	molecular	weight.	
Proteins	 were	 transferred	 into	 a	 nitrocellulose	membrane	 during	 90	minutes	 at	 500	mA,	
immersed	 in	a	transfer	buffer	(for	1	L:	Ethanol	20%,	0,58	g	Tris	 (48	mM),	0,29	g	Glycin	(39	
mM),	SDS	10%).	For	 this,	 the	membrane	was	placed	next	 to	 the	gel,	 sandwiched	between	
blotting	paper	and	sponges	and	clamped	tightly	between	solid	brackets.	The	nitrocellulose	
membrane	 was	 stained	 with	 Ponceau	 Red	 to	 check	 for	 the	 quality	 of	 the	 transfer,	 then	
washed	thoroughly	with	water,	tris-buffered	saline	(TBS;	for	500	mL:	Tris	12.1	g,	NaCl	87,7	g,	
H20	up	to	500	mL)	and	TBST	(TBS	+	0.1%	Tween	20)	until	the	membrane	was	completely	de-
stained.	
To	 prevent	 non-specific	 interactions,	 it	 was	 further	 incubated	 1	 h	 with	 odyssey	 blocking	
buffer	 (PBS	 3:1	 TBS)	 at	 room	 temperature	 to	 prevent	 non-specific	 interactions.	 The	
membranes	 were	 incubated	 ON	 with	 the	 primary	 antibody	 solution	 prepared	 in	 odyssey	
blocking	buffer	with	0.1%	tween	20	as	indicated	in	table	1.	
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The	next	day,	the	membrane	was	washed	3	times	with	TBST,	5	min	per	wash	with	shaking	to	
remove	unbound	antibodies.	
AlexaFluor	®	488	or	633	conjugated	secondary	antibody	was	used	for	a	1-hour	incubation	at	
room	temperature,	with	gently	shaking	and	protected	from	light.		
The	membrane	was	then	washed	2	times	with	TBST	and	once	with	PBS,	5	min	per	wash	and	
put	under	infrared	light	for	the	detection	and	identification	of	the	protein	bands,	which	will	
next	be	interpreted	and	analyzed	by	densitometry.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
10. Total	RNA	extraction	and	precipitation		
	
The	 total	 RNA	 was	 extracted	 using	 RNAzol®	 reagent	 (Sigma)	 according	 to	manufacturer’s	
instructions.	Briefly,	cells	were	thaw	from	-80°C	and	lyzed	in	200	µL	RNAzol	RT	and	then	put	
in	 an	 Eppendorf	 tube	 with	 80	 µL	 of	 RNase-free	 water	 during	 5-15	 min.	 Centrifugation	
separated	the	mixture	into	a	semisolid	pellet	(containing	DNA,	proteins	and	polysaccharides)	
and	an	upper	supernatant	(containing	the	RNA)	that	we	carefully	placed	in	a	new	tube	with	
2.5	volume	of	isopropanol	to	precipitate	the	RNA.	After	washing	with	300	µL	of	75%	ethanol	
to	 the	 RNA	 pellet	 was	 solubilized	 in	 15	 µL	 RNase-free	 water	 on	 ice	 to	 avoid	 unexpected	
degradation.	 The	 quality	 of	 the	 purified	 RNA	was	 further	 assessed	 by	 spectrophotometry	
technique	using	NanoDrop®	technology.		
	
	
	
	
Name	 Origin	 Fabrication	 Dilution	
	Primary	antibodies	(IgG)		 	 	
E2F1	 rabbit		 Santa	Cruz	 1:500	
CDK4	 rabbit	 Santa	Cruz	 1:500	
GFP	(G6)	 mouse	 Santa	Cruz	 1:2000	
Histone	(H3)	 rabbit	 Santa	Cruz	 1:10000	
	 	 	 	
	Secondary	antibodies	(IgG)	 	 	
alexa	fluor® 488	anti-mouse goat	 Invitrogen	 1:15000	
alexa	fluor® 488	anti-rabbit	 goat	 Invitrogen	 1:15000	
alexa	fluor® 633	anti-mouse	 goat	 Invitrogen	 1:15000	
alexa	fluor® 633	anti-rabbit	 goat	 Invitrogen	 1:15000	
Table	1:	List	of	antibodies	used	during	the	experiment;	Alexa	fluor® 488	emitted	green	
light	at	a	wave	length	of	519	nm,	whereas	Alexa	fluor® 633	emitted	red	light	at	647	nm.	
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11. RT-PCR		
	
Our	objective	was	to	assess	the	amount	of	mRNA	of	specific	genes.	To	that	aim	we	needed	
first	 to	 produce	 the	 cDNA	 corresponding	 to	 these	 mRNAs.	 Reverse	 transcription	 (RT)	
reaction	is	a	technique	that	allows	the	transcription	of	RNA	into	cDNA.	It	 is	done	thanks	to	
an	 enzyme,	 the	 reverse	 transcriptase,	which	 is	mixed	with	 random	primers	 to	 ensure	 the	
initiation	of	the	synthesis	of	cDNA	with	mRNA.	RT	also	requires	a	mix	of	nucleotides	for	the	
DNA	synthesis	and	various	RT	buffers	
The	 RNA	 solution	was	 standardized	 to	 a	 100	 ng/µL	 concentration	 in	 10	 µL	 of	 RNAse	 free	
water.	RTs	were	performed	in	20	µL	of	solution	per	200	µL	PCR	tubes,	with	10	µL	of	2X	RT	
master	mix	(see	table	2).	The	tubes	were	loaded	on	the	thermal	cycler	which	allows	the	RT	
reactions	 to	 happened	 according	 to	 a	 4-steps	 cycle	 program	as	 seen	 on	 table	 3.	 To	 avoid	
RNase	contamination,	all	these	steps	were	performed	with	RNase-free	consumables	and	in	a	
RNase-free	environment.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Component	 Volume	per	reaction	
10X	RT	buffer	 2.0	µL	
25X	dNTP	mix	(100mM)	 0.8	µL	
10X	RT	random	primers	 2.0	µL	
MultiScribe™	Reverse	Transcriptase	 1.0	µL		
RNase	inhibitor		 1.0	µL	
Nuclease-free	H20	 3.2	µL	
Total	per	reaction		 10.0	µL	
	 step	1	 step	2	 step	3	 step	4	
temperature	
(C°)	
25°C	 37°C	 85°C	 4°C	
time	
(minutes)	
10		 120	 5	 undefined	
Table	2:	2X	RT	master	mix	receipt.	The	volumes	presented	on	this	table	are	
for	one	unique	reaction.	The	master	mix	was	prepared	after	calculation	for	
the	required	number	of	reactions.	
Table	3:	Thermal	cycling	program	for	reverse	transcriptase	reactions.	
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12. QPCR	analysis	
	
Real-time	 Polymerase	 Chain	 Reaction	 (real-time	 PCR)	 or	 quantitative	 PCR	 (qPCR)	 is	 a	
technique	 of	 biology	 based	 on	 the	 amplification	 of	 DNA	 or	 cDNA.	QPCR	monitors	 in	 real-
time,	the	amount	of	a	known	amplicon	in	a	sample.	Since	this	cDNA	comes	from	a	mRNA	of	
a	specific	gene,	it	will	give	us	the	indirect	expression	of	our	gene	of	interest.	
A	96-well	reaction	plate	was	 loaded	with	a	2X	qPCR	SYBR	green	master	mix	10	µL,	2,5	µM	
primers	 (2,5	 µL	 forward	 primers	 and	 2,5	 µL	 reverse	 primers)	 for	 Chk1,	 E2f4	 and	 FoxM1	
(sequence	 available	 on	 table	 4)	 were	 used	 for	 the	 PCR,	 with	 5	 µL	 of	 cDNA	 sample.	 We	
performed	a	serial	dilution	until	a	final	amount	of	0,05	ng	of	cDNA.	Amplifications	were	done	
according	 to	 the	 manufacturer’s	 protocol	 using	 the	 LightCycler	 ®	 96	 (Roche)	 which	 also	
allows	to	analyse	the	standard	and	melting	curves	and	the	average	Ct	of	each	reactions.		
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Gene	 Sequence		
Chk1	(forward)	 5’-CTGGAGTACTGTAGTGGAGGAG-3’	
Chk1	(reverse)	 5’-CCGAAATACCGTTGCCAAGCC-3’	
E2f4	(forward)	 5’-CTCAATGGCCAGAAGAAGTACC-3’	
E2f4	(reverse)	 5’-CTCACTGCAATCTCAGATGTCG-3’	
FoxM1	(forward)	 5’-GCTTGCGATTCTCGATGGAGAG-3’	
FoxM1	(reverse)	 5’-CTGGACACTGCCACCTCTTG-3’	
Table	4:	Sequence	of	the	forward	and	reverse	primers	used	during	the	
experiment.	
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Results	
	
• Set	up	of	661W	cell	culture	conditions	to	obtain	optimal	conditions	for	miRNA	
transfection	
	
To	better	understand	 the	molecular	basis	of	eye	diseases	and	 facilitate	 the	 investigations,	
cell	lines	are	usually	used.	The	661W	cell,	is	a	well-known	mouse	photoreceptor-like	cell	line	
(35).	It	is	derived	from	a	retinal	tumor	and	express	several	markers	of	cone	photoreceptors.	
Because	these	cells	are	proliferating	and	because	the	miRNA	we	aim	to	test	may	affect	cell	
proliferation,	we	hypothesized	that	this	cell	line	may	be	appropriate.	To	perform	an	efficient	
miRNA	transfection	on	the	661W	cells,	we	wanted	to	have	optimal	conditions.	This	 is	why	
we	 decided	 to	 observe	 and	 understand	 their	 growth	 kinetic	 in	 12-well	 plate	 and	 24-well	
plate.		
Various	amounts	of	661W	cells	were	put	on	culture	and	we	evaluated	the	confluence	of	the	
cells	after	a	certain	amount	of	time.	For	each	well,	we	wanted	to	know	which	amount	of	cell	
was	required	for	having	a	70-80%	confluence	the	next	day.	This	amount	of	confluence	was	
recommended	 by	 the	 manufacturer	 for	 an	 efficient	 lipofectamine®	 transfection	 of	 our	
plasmid	expressing	miR-31.	
For	the	12-well,	we	put	on	culture	80’000,	120’000,	160’000	and	200’000	cells	per	mL,	and	
for	the	24-well	plate	40’000,	60’000,	80’000	and	100’000	cells	per	mL,	then	observed	their	
density	and	confluence	after	24	hours,	48	hours	and	72	hours.	The	results	are	presented	on	
figure	1.	We	observed	a	linear	correlation	between	the	number	of	cell	seeded	and	the	time	
required	to	achieve	confluence.		
The	 cell	 confluences	 were	 subjectively	 measured	 with	 microscope.	 In	 the	 two	 plates,	
200’000	cells/mL	corresponded	to	about	60%	to	70%	of	confluence,	400’000	cells/mL	were	
about	80%	and	600’000	cells/mL	and	more,	exceeded	the	95%	of	confluence.		
For	the	12-well	plate,	we	observed	that	80’000	cells	seeded,	allowed	to	reach	about	50-60%	
of	confluence	after	24	hours	and	almost	80%	after	48	hours,	whereas	120’000	cells	seeded	
reached	the	confluence	of	60-70%	at	24	hours.	
In	a	parallel	way,	we	observed	for	the	24-well	plate,	a	bit	more	than	70%	of	confluence	for	
the	40’000	density	after	48	hours.	The	wells	with	60’000	cells	per	mL	reached	almost	60-70%	
confluence	 at	 24	 hours	 and	 over	 80%	 after	 48	 hours.	 These	 two	 values	 were	 not	 so	
dissimilar,	 but	 we	 decided	 to	 stick	 to	 the	 60’000	 cells	 per	 mL.	 Indeed,	 all	 the	 following	
density	of	cells	tested	for	the	12-well	plate	and	the	24-well	plate	(160’000,	200’000	cells/mL	
and	80’000	and	100’000	cells/mL	respectively)	were	rapidly	too	confluent	and	reached	more	
than	95%	of	confluence	too	briefly	so	that	we	were	not	comfortable	with	our	study.	
Therefore,	we	concluded	that	120’000	cells	seeded	per	mL	on	the	12-well	plate	and	60’000	
cells	 per	mL	 for	 the	 24-well	 plate	were	 the	 optimal	 amount	 of	 661W	 cells	 to	 achieve	 the	
cellular	density	we	needed	for	the	miR-31	transfection	protocol.	
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Figure	1:	Time	course	of	661W	cell	density	in	function	of	cell	number	seeded	initially;	(A)	is	the	
12-well	 plate	 study	 and	 (B)	 is	 the	 24-well	 plate	 study.	 The	 errors	 bars	 indicate	 the	 SEM.	 The	
cellular	density	increased	proportionally	to	time	and	number	of	cells	seeded.	
	
(A)	
(B)	
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• Effective	661W	cell	transfection	with	GFP	and	miR-31	cDNA:	fluorescent	
detection	on	microscope	
	
As	 we	 wanted	 to	 evaluate	 the	 effect	 of	 the	 miR-31	 overexpression	 on	 the	 661W	 cell	
proliferation,	 we	 performed	 a	 transfection	with	 a	 plasmid	 expressing	 the	miR-31	 gene	 as	
well	as	the	Green	Fluorescent	Protein	(GFP)	gene	and	let	the	cells	express	these	genes	for	at	
least	 48	 hours.	With	 the	 reporter	 gene,	 we	 can	 detect	 the	 expression	 of	 the	 transfected	
plasmid	on	microscope,	and	therefore,	validate	the	transfection	in	the	cells.	
The	 lipofectamine	 transfection	 experiments	 were	 performed	 under	 three	 conditions,	 first	
with	the	HBSS	only	for	the	negative	control,	the	second	with	a	plasmid	coding	only	for	GFP	
as	the	positive	control	and	the	last	with	the	miR-31	plasmid.	The	transfected	cells	were	then	
analysed	with	a	fluorescent	light	microscope,	as	seen	on	the	microscope	images	presented	
on	 figure	 2.	 We	 estimated	 a	 transfection	 efficiency	 below	 20%	 and	 10%	 for	 the	 miR-31	
plasmid	and	for	the	control	plasmid,	respectively.	
	
	
• WB	analyse	of	the	661W	cells	transfected	with	miR-31	
	
Cell	 lysate	was	 generated	48	hours	 after	 the	 transfection.	 Therefore,	 the	 transfected	 cells	
had	this	time	lapse	to	overexpress	the	miR-31	and	undergo	the	molecular	changes	that	we	
expected	to	 identify.	We	harvested	the	whole	cell	population	 in	 the	12-well,	 the	cells	 that	
received	an	efficient	transfection	and	the	ones	that	did	not.	
The	total	protein	concentration	for	each	sample	was	measured	with	BCA	assays	as	explained	
in	 materials	 and	 methods	 section	 and	 then	 diluted	 on	 the	 same	 concentration	 for	 the	
Western	Blot.	 	 The	 red	ponceau	staining	 revealed	 that	 the	WB	 transfer	on	 the	membrane	
was	 successful	 (figure	 3).	 	 We	 observed	 that	 some	 samples	 contain	 more	 protein,	 for	
example	in	GFP-1,	GFP-2,	miR-31-1,	miR-31-2,	miR-31-3	and	miR-31-4.	This	variability	may	be	
due	to	any	previous	step	in	the	manipulation	(protein	preparation,	gel	loading	etc.)	or	to	the	
treatment	and	must	be	taken	into	account	for	the	interpretation	of	the	results.	
	
	
• Test	of	the	expression	of	the	vectors	
	
GFP	 sequence	 was	 present	 in	 both	 plasmids	 and	 served	 to	 validate	 the	 efficiency	 of	 the	
transfection.	 The	 GFP	 protein	 is	 known	 to	 have	 a	 molecular	 weight	 of	 27	 kDa,	 which	
corresponds	precisely	where	 the	band	 is	 revealed	on	 figure	4.	We	can	 therefore	 conclude	
that	 there	 is	 no	 GFP	 protein	 in	 the	 HBSS-1,	 HBSS-2,	 HBSS-3	 and	 HBSS-4	 samples	 which	
correspond	to	the	negative	control.	As	expected,	in	the	GFP-1,	GFP-2,	GFP-3,	GFP-4,	miR-31-
1,	miR-31-2,	miR-31-3,	miR-31-4	samples,	GFP	protein	was	well	expressed.	
	
	
	
	
	
	
	
	
	 -	16	-	
	
Figure	2:	Transfection	of	661W	cells.	(A,	D)	Phase	contrast	picture	of	cells	after	transfection	(Black	
and	 white.	 (B,	 C)	 Green	 fluorescent	 protein	 (GFP)	 expression	 48	 h	 after	 miR-31	 transfection	 of	
661W	 cells.	 (E,	 F)	 GFP	 expression	 after	 GFP-scramble	 control	 transfection	 of	 661W	 cells.	 We	
estimate	 a	 transfection	 efficiency	 of	 <20%	 for	 the	 miR-31	 construct	 and	 <10%	 for	 the	 control	
plasmid.	Scale	bars	are	shown	in	each	panel.	
A	
B	
	
C	
D	
	
E	
F	
miR-31	transfection		 GFP	transfection		
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• Reduced	E2F1	in	miR-31	transfected	661W	cells	
	
The	listed	antibodies	on	table	1	were	applied	to	the	membrane	as	explained	in	materials	and	
methods.	
Anti-E2F1	and	anti-CDK4	antibodies	were	used	with	the	anti-Histone	H3	antibody	in	order	to	
have	a	protein	level	as	a	normalizing	control.	E2F1	and	CDK4	were	the	protein	of	interest	as	
they	 are	 cell	 cycle	 proteins,	 and	we	 expected	 their	 level	 to	 decrease	 in	 the	 experimental	
condition,	compared	to	the	control	condition.	
Figure	5	 shows	 the	WB	analysis,	 the	 first	membrane	 (A)	was	 incubated	with	 E2F1	and	H3	
antibody	 solution	 and	 the	 second	 membrane	 (B)	 with	 CDK4	 and	 H3	 antibodies.	 The	
molecular	 weight	 corresponding	 to	 the	 migration	 of	 the	 protein	 visualized	 on	 the	
Figure	 3:	 Protein	
transfer	 evidenced	 by	
Red	 ponceau	 staining.	
The	 left	 lane	 is	 the	
protein	 marker	 used	
as	 ladder	according	to	
the	 molecular	 weight	
(in	kDa)	as	indicated.	
	
Figure	4:	WB	analysis	of	a	membrane	incubated	with	GFP	protein	antibodies.	Protein	band	
corresponding	to	27	kDa	molecular	weight	are	visualized	in	the	GFP-1,	GFP-2,	GFP-3,	GFP-
4,	miR-31-1,	miR-31-2,	miR-31-3,	miR-31-4	samples,	but	not	present	in	the	HBSS-1,	HBSS-2,	
HBSS-3	and	HBSS-4	samples.	
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membranes	indicates	us	that	the	proteins	E2F1	(61	kDa),	Histone	H3	(18	kDa)	and	CDK4	(34	
kDa)	are	detected	on	the	WB.	
Then,	 we	 compared	 and	 analysed	 with	 densitometry	 the	 intensity	 of	 the	 bands,	 which	
correspond	 to	 the	protein	concentration.	Then,	 the	values	 for	E2F1	and	CDK4	bands	were	
normalized	 with	 each	 corresponding	 H3	 protein	 signal.	 For	 each	 quadruplicate,	 we	
calculated	 the	 average,	 the	 standard	 error	 of	 the	 mean	 (SEM)	 and	 p	 values	 (levels	 of	
significance:	p	<	0.01	is	considered	as	highly	significant	(**),	p	<	0.05	as	significant	(*)	and	p	>	
0.05	as	non-significant	(ns)).	
	
The	 densitometry	 (figure	 6)	 showed	 that	 the	 amount	 of	 E2F1	 protein	 was	 significantly	
reduced	 in	 the	 miR-31	 sample	 compared	 to	 the	 non-treated	 (NT)	 sample	 and	 the	 GFP-
treated	sample	(GFP	treated:	1.614	±	0.166	SEM,	n	=	4;	miR-31	treated:	0.444	±	0.108,	n	=	4;	
p	 =	 0.001).	 Regarding	 the	 CDK4	 densitometry,	 we	 observed	 a	 slight,	 but	 unsignificant	
difference	 between	 the	 GFP-treated	 and	 the	 miR-31	 treated	 samples.	 In	 conclusion,	 this	
result	 revealed	that	a	48	hours	miR-31	overexpression	 in	661W	cells	 induce	a	reduction	 in	
E2F1	protein	expression.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5:	Effect	of	miR-31	overexpression	on	cell-cycle	proteins	 regulating	G1	and	S-phases.	WB	
analysis	 of	 the	 membrane	 incubated	 with	 antibodies	 for	 E2F1	 and	 H3	 protein	 (A)	 and	 the	
membrane	incubated	with	antibodies	for	CDK4	and	H3	protein	(B).	Note	the	reduced	level	of	E2F1	
after	miR-31	transfection.	
	
B	
A	
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• Spectrophotometry:	Total	RNA	concentration	in	the	transfected	661W	cell	
samples	
	
Another	way	for	evaluating	the	expression	of	a	gene,	is	to	quantify	the	mRNA	amount	of	the	
gene	of	 interest.	To	that	purpose,	we	extracted	and	isolated	the	total	RNA	from	the	661W	
cells,	48	hours	after	their	transfection,	according	to	the	protocol	previously	described.		
The	extracted	pellet	was	submitted	to	a	Nanodrop®	spectrophotometry	measurement	(table	
5)	and	the	purity	of	the	sample	was	considered	satisfactory	when	the	260/280	ratio	was	over	
1.8.	Sample	#1	is	a	blank	measure	and	sample	#7,	#13	and	#14	were	eliminated	because	of	a	
too	 little	RNA	concentration.	The	RNA	concentration	of	 the	 samples	varies	between	717.6	
ng/µL	 (for	 the	4th	GFP	 sample)	and	982.7	ng/µL	 (for	 the	3rd	GFP	 sample)	and	 the	260/280	
ratio	 varied	 between	 1.98	 (for	 GFP-4	 and	 miR-31-1	 samples)	 and	 2.01	 (for	 the	 HBSS-1	
sample).	We	normalized	the	concentration	of	the	following	samples:	HBSS-1,	HBSS-2,	HBSS-
3,	 HBSS-4,	 GFP-1,	 GFP-3,	 GFP-4,	 miR-31-1,	 miR-31-2	 and	 miR-31-3	 and	 performed	 the	
reverse	transcription	reactions.		
	
	
	
	
	
	
	
Figure	6:	Effects	of	miR-31	transfection	on	cell-cycle	proteins	in	the	661W	cell;	Expression	levels	
of	 E2F1	 (A)	 and	 CDK4	 (B)	 were	 analyzed	 by	WB	 48	 h	 after	 the	 transfections	 of	 the	 different	
constructs.	Errors	bars	indicate	the	SEM.	Note	the	highly	significant	reduction	of	E2F1	in	the	miR-
31	 group	 (p	 =	 0.001).	 No	 significant	 differences	were	 observed	 between	 groups	 for	 the	 CDK4	
expression.	
	
(A)	 (B)	
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• Decreased	Chk1	and	E2f4	gene	expressions	in	miR-31	transfected	661W	cell	
	
The	qPCR	 is	 the	 technique	 that	allowed	us	 to	quantify	 the	mRNA	amount	of	our	genes	of	
interest.	During	48	hours,	the	transfected	661W	cells	produced	mRNA	under	three	different	
conditions.	Our	hypothesis	was	 that	Chk1,	E2f4	and	FoxM1	genes	might	be	 less	expressed	
with	a	miR-31	overexpression,	because	they	are	regulating	the	cell	cycle.	So	we	performed	
an	experiment	based	on	one	qPCR	amplification	of	cDNA	using	forward	and	reverse	primers	
for	Chk1,	E2f4,	FoxM1	and	Mrl8	genes	and	measured	the	load	of	amplicon	for	each	of	them	
in	3	replicates	(n	=	1).	
A	comparative	Ct	method	(∆∆Ct	method)	was	used	for	the	data	analysis	(table	6).	The	results	
of	 the	 genes	 of	 interest	 (Chk1,	 E2f4,	 FoxM1)	 were	 normalized	 with	 a	 gene	 ubiquitously	
expressed	 in	 different	 cells	 (Mrl8).	 The	 values	 of	 the	 two	 treated	 conditions	 (GFP	
transfection	 and	miR-31	 transfection)	were	 then	 compared	with	 the	NT	 condition	 (HBSS).	
Figure	7	presents	the	expression	fold	changes	for	each	gene	in	the	GFP	treated	and	miR-31	
treated	samples,	relative	to	the	NT.	
The	expression	fold	change	for	Chk1	and	E2f4	are	lower	in	the	miR-31	condition	than	in	the	
GFP	condition.	So,	with	the	miR-31	treatment,	we	do	observe	a	reduction	of	expression	of	
Chk1	 gene	 and	 E2f4	 gene.	 Unfortunately,	 with	 p	 values	 respectively	 at	 0.097	 and	 0.274,	
these	results	are	not	significant.	Concerning	the	FoxM1	gene,	the	expression	was	reduced	in	
experiment	(miR-31)	and	control	conditions	(GFP)	 in	comparison	to	the	NT,	so	this	 is	not	a	
relevant	 result	 for	 the	 experiment	 condition.	 The	 low	 expression	 fold	 change	 in	 the	 GFP-
treated	 samples	 may	 reveal	 a	 mishandling	 problem.	 Altough	 all	 these	 findings	 are	
statistically	 not	 significant,	 the	 reduction	 of	 the	 Chk1	 gene	 expression	 in	 661W	 cells,	 48	
hours	after	a	miR-31	transfection	is	suggestive	of	a	regulating	role	from	miR-31	on	the	cell	
cycle.	Further	experiments	are	needed	to	confirm	these	results.	
	
	
	
	
Table	 5:	 Screenshot	 of	 Nanodrop®	 table;	 with	 Sample	 ID,	 nucleic	 acid	 concentration	
(ng/µL),	 260	 and	 280	 wavelength	 absorbance,	 260/280	 absorbance	 ratio.	 DEPC	 is	
diethylpyrocabonate-treated	water	(blank	measurement).		
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GFP	treated			
(control	condition)	
miR-31	treated	
(experiment	condition)	
FoxM1	fold	change		 0.0762	 0.3458	
Chk1	fold	change	 0.8878	 0.5998	
E2f4	fold	change	 0.9964	 0.7364	
Table	6:	Effects	of	miR-31	transfection	in	661W	cells	on	gene	expressions	of	genes	involved	
in	cell	cycle	regulation.	Mrl8	is	the	reference	gene	used	for	normalizing	the	data,	and	the	
genes	of	interest	are	Chk1,	E2f4	and	FoxM1	(n=3).	
	
Figure	7:	Expression	fold	changes	for	Chk1,	E2f4	and	FoxM1	gene	after	miR-31	transfection	
in	 661W	 cells.	 The	 results	 are	 expressed	 for	 the	 GFP-treated	 and	 the	 miR-31-treated	
conditions,	 relative	to	the	non-treated	(NT)	condition.	Errors	bars	 indicate	the	SEM	(n=3).	
Note	that	the	differences	are	non-significant.	
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Discussion	
	
	
Various	pathways	are	 suspected	 to	be	 involved	 in	 the	 retinal	neurodegeneration,	 as	PARP	
overactivation	(16),	cGMP	and	PKG	(12)	or	calpain-type	protease	(13).	Preliminary	results	in	
the	laboratory	showed	that	miR-31	concentration	was	reduced	in	degenerating	Rd1	retina,	
which	led	us	to	evaluate	its	influence	on	cell	cycle	markers.	CDK2,	CDK4,	CDK6	and	E2F1	are	
associated	with	neurodegenerative	cell	death	(18).	E2F	proteins	do	have	a	major	role	in	cell	
cycle	progression	(36)	involving	a	huge	pathway	with	several	proteins.	One	of	them	is	BMI1,	
which	 is	 an	 upstream	 protein	 of	 this	 pathway	 and	 produces	 a	 prolonged	 photoreceptor	
survival	when	suppressed	(18).	The	cell	cycle	role	in	the	cell	death	is	crucial.	We	focused	our	
study	on	CDK4	and	E2F1	proteins	as	well	as	E2f4,	FoxM1	and	Chk1	genes.	Our	data	highly	
suggests	that	a	miR-31	overexpression	is	associated	with	a	reduced	E2F1	protein	level.	This	
finding	 does	 not	 yet	 lead	 to	 the	 full	 comprehension	 of	 cell	 death	mechanism	 in	 neuronal	
degeneration,	but	 it	makes	a	potential	 link	between	E2F1	protein	and	miR-31	 function,	 at	
least	 in	 661W	 cells.	 And	 because	 a	 reduced	 level	 of	 E2F1	 produce	 neuroprotective	 effect	
(18),	we	can	suggest	that	miR-31	overactivation	could	contribute	to	photoreceptor	survival.	
In	 the	 present	 results	 FoxM1,	 Chk1	 and	 E2f4	 are	 not	 significantly	 affected	 by	 miR-31	
overexpression.		We	may	also	suspect	them	to	be	indirectly	targeted	by	miR-31,	because	this	
molecule	 regulates	 cell	 cycle	 proteins,	 inducing	 cell	 death	 (37)	 or	 inhibiting	 cell	 growth	 in	
other	type	of	tissue	(38).	FoxM1	recently	has	been	associated	with	other	miRs	as	the	miR-
214	(39),	miR-374b	(40)	and	miR-34a	(41)	and	they	all	downregulate	the	transcription	factor.	
MiRs	are	more	and	more	studied	and	their	role	in	regulating	the	cell	cycle	is	well	established	
(28),	 therefore,	 our	 hypothesis	 seems	 to	 be	 realistic.	 With	 this	 study,	 we	 come	 to	 the	
suggestion	 that	 if	 the	 low	 concentration	 of	miR-31	 in	Rd1	 retina	 could	 be	 increased,	 the	
amount	 of	 E2F1	 protein	 would	 drop	 and	 so	 induce	 a	 neuroprotective	 effect.	 The	 link	
between	E2F1	and	miR-31	must	be	confirmed.	
Our	experiment	contains	limitations	that	are	important	to	notice.	The	transfection	efficiency	
was	probably	inferior	to	20%	for	all	transfection	performed,	despite	our	attempt	to	find	the	
ideal	transfection	conditions	with	optimal	cell	culture,	we	think	that	transfection	efficiency	
could	 be	 increased,	 and	 so	 improve	 the	 expression	 of	 miR-31	 which	 may	 produce	 more	
considerable	 results.	 Considering	 this	 percentage	 of	 transfection,	 the	 gene	 expression	
decrease	 (or	 increase)	 is	 thus	much	more	pronounced,	because	 it	occurred	only	 in	around	
20%	of	the	cells	investigated.	Moreover,	all	our	analysis	was	performed	on	the	661W	cells	48	
hours	 after	 the	 transfection,	 a	 more	 extended	 period	 of	 time	 exposed	 to	 a	 miR-31	
overexpression	also	could	contribute	to	different	results.	
However,	 as	 this	 experiment	was	 done	 in	 a	 short	 amount	 of	 time,	WB	 analysis	 and	 qPCR	
could	not	be	done	for	all	the	proteins	and	gene	of	interest,	so	these	results	can	be	reinforced	
by	 validating	 the	 reduction	 of	 E2F1	 with	 qPCR.	 Next	 step	 could	 be	 to	 evaluate	 a	 miR-31	
overexpression	influence	on	other	cell	cycle	proteins.	The	fact	that	this	study	was	done	on	in	
vitro	661W	cell	line	also	has	to	be	taken	into	account,	as	all	this	should	be	confirmed	with,	
for	 example,	 Rd1	 retinas,	 and	 later,	 hopefully,	 with	 in	 vivo	 experiments	 in	 mice.	 If	 these	
results	are	confirmed,	a	test	to	block	the	cell	cycle	re-entry	by	miR-31	overexpression	in	vivo	
in	animal	models	of	retinal	degeneration	would	be	interesting	to	study	a	potential	slowdown	
of	the	photoreceptor	degeneration	process.	
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It	 is	worth	 remembering	 that	 retinal	 degeneration	 and	more	 classic	 neurodegeneration	 in	
the	rest	of	the	CNS	are	very	similar,	some	future	findings	on	retinal	degeneration	could	lead	
far	beyond	the	retinitis	pigmentosa	and	the	ophthalmologic	field.	
	
Conclusion	
	
Reduced	miR-31	and	reactivation	of	cell	cycle	protein	 in	degenerating	Rd1	 retina	 led	us	 to	
the	 hypothesis	 that	 the	 degenerating	 process	 could	 be	 slowed	 down	 by	 blocking	 the	 cell	
cycle	re-entry	with	miR-31	augmentation.	The	first	step	of	the	theory	was	confirmed	by	this	
experiment.	Indeed,	48	h	after	a	miR-31	transfection,	661W	cells	had	a	reduced	E2F1	protein	
concentration.	The	possible	link	between	E2F1	and	miR-31	is	important	because	their	role	in	
neurodegeneration	 may	 be	 crucial.	 Obviously,	 further	 studies	 need	 to	 legitimate	 our	
findings,	 but	 this	 means	 that	 miR-31	 overexpresion	 could	 potentially	 produce	 a	
neuroprotection	 in	 degenerating	 cells.	 Next	 events	 seem	 to	 be	 promising	 as	 new	
pharmacological	 therapies	 could	 be	 developed	 to	 reduce	 the	 cell	 death	 process	 in	
degenerating	retinal	diseases.	
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